Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) announced that it has been issued a patent from the United States Patent and Trademark Office (USPTO) covering RX-21101 for …
When a tumor-targeted therapy company advances in clinical trials, pay attention. Rexahn Pharmaceuticals (NYSEMKT:RNN) should be closely watched.
Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN) announced preliminary efficacy data for RX-3117 in an ongoing Phase Ib/IIa clinical trial in patients with metastatic pancreatic cancer …
Yesterday, Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) announced it will be presenting preliminary data for a Phase Ib/IIa trial of metastatic pancreatic cancer drug RX-3117 …
Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) announced it has entered into a definitive agreement with institutional investors to purchase 24 million shares of its common stock …
Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN), a clinical stage biopharmaceutical company developing next generation targeted therapeutics for the treatment of cancer, today announced it has initiated …
Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced financial results for the second …
Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced the appointment of Lisa Nolan, …
Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing next generation therapeutics for the treatment of cancer, announced today that Phase I …
Rexahn Pharmaceuticals, Inc. (NYSE:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, announced financial results for the first …
